“Chemoradiotherapy with a cisplatin-based chemotherapy regimen is the standard of care for patients with HNC, but is associated with a high incidence of CRT-induced OM. OBPC and oral care programs are insufficient in reducing OM incidence; there is a need for additional interventions to prevent and treat OM.”
https://www.oncologynurseadvisor.com/side-eff...le/757350/
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links